Overall Program Sample Clauses

Overall Program. The Parties shall collaborate in the field of Obesity under the terms and conditions set forth in this Agreement and in Research Program. The activities to be undertaken in the course of Research Program are set forth in Schedule 2.1 (the "Research Plan") that may be amended from time to time upon the mutual agreement of the Parties.
Sample 1
AutoNDA by SimpleDocs
Overall Program. RMI will create, develop and manage the market impact for the Products in conjunction with, working with, and on behalf of Algal. This process shall include the creation, orchestration and management of collaborative and mutually beneficial proprietary-type sourcing relationships that include the branding, licensing, marketing and distributing of such products to provide highly effective and desirable benefits to consumers through powerful, efficient and effective consumer focused marketing programs. Using multifaceted, multi-channel, coordinated and synchronized promotion and branding strategies, RMI shall create demand-pull-through market programs, extending from source to consumer, facilitating simultaneous and sequential multiple channels, categories and paths of supply to deliver product benefits to the largest population of consumers while minimizing the market shrinkage consequences from negative competitive conflicts. RMI’s marketing strategy will follow the general terms described in Exhibit B and the general global market development strategy similar to such strategy described in Exhibit C, in both cases at RMI’s sole and exclusive expense. RMI shall act in accordance with the marketing strategy and market development strategy, as agreed between the parties and as modified from time to time, to conduct the included marketing and market development activities, all at RMI’s cost.
Sample 1

Related to Overall Program

  • Development Program A. Development Activities to be Undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Development Activities NovaDel shall not be required to commence any Development Activities until Licensee has paid at least twenty-five percent (25%) of the non-refundable License Fee described in Section 4.4.

  • Program This agreement (the “Agreement”) sets forth the understandings between the Issuer and the Dealer, each named on the cover page hereof, in connection with the issuance and sale by the Issuer of its short-term promissory notes (the “Notes”) through the Dealer. Certain terms used in this Agreement are defined in Section 6 hereof. The Addendum to this Agreement, and any Annexes or Exhibits described in this Agreement or such Addendum, are hereby incorporated into this Agreement and made fully a part hereof.

  • Development Plan As defined in Section 3.2(a).

  • Business Travel, Lodging, etc Employer shall reimburse Executive for reasonable travel, lodging, meal and other reasonable expenses incurred by him/her in connection with his/her performance of services hereunder upon submission of evidence, satisfactory to Employer, of the incurrence and purpose of each such expense and otherwise in accordance with Employer’s business travel reimbursement policy applicable to its senior executives as in effect from time to time.

  • The Program The Program in object code form and related Documentation provided to HP hereunder are deemed non-confidential, and HP is not under any obligation to SA to restrict access to or use of such Program in object code form or related Documentation, provided HP complies with the terms of this Agreement.

  • Development Plans 4.3.1 For each Licensed Indication and corresponding Licensed Product in the Field, Licensee will prepare and deliver to Licensor a development plan and budget (each a “Development Plan”). The initial Development Plans for each Licensed Indication will be delivered within […***…] after the Grant Date for such Licensed Indication.

  • Offering Services The Manager shall manage and supervise:

  • Commercial Supply Celgene shall Manufacture and supply all Commercial Supplies.

  • Clinical Supply Takeda will provide to Licensee[***] the amount of TAK-385 Licensed Compound or TAK-385 Licensed Products needed by Licensee to complete all Clinical Trials contemplated by the TAK-385 Development Plan (estimated by Licensee as of the Effective Date to be [***]), solely to the extent that Takeda can supply such TAK-385 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. Licensed Compound or TAK-385 Licensed Products (a) from its supply of TAK-385 Licensed Compound or TAK-385 Licensed Products in existence as of the Effective Date and which supply can be used for its intended purposes without further re-processing (the “Initial Clinical Supply”) and (b) after retaining the amount needed by Takeda for Clinical Trials in the Takeda Territory. Takeda will also provide to Licensee, at [***] any additional supplies of TAK-385 Licensed Compound or TAK-385 Licensed Products in excess of the Initial Clinical Supply needed by Licensee to complete all Clinical Trials contemplated by the TAK-385 Development Plan. Within [***] days after the Effective Date, the Parties will enter into a manufacturing and supply agreement (the “Takeda Clinical Manufacturing and Supply Agreement”), which will govern the terms and conditions of the Manufacturing and supply of the TAK-385 Licensed Compound and TAK-385 Licensed Products (including the Initial Clinical Supply) by Takeda to Licensee for Development purposes, including the exact quantities and the timelines for delivery. The Parties will negotiate the terms and conditions of such Takeda Clinical Manufacturing and Supply Agreement in good faith for a period of [***] days (as may be extended upon agreement of the Parties). As part of the negotiation related to the Takeda Clinical Manufacturing and Supply Agreement, the Parties shall discuss in good faith the ability of Takeda to supply to Licensee [***]. If the Parties have not entered into a definitive agreement within such negotiation period, then the final terms and conditions of such agreement will be resolved in accordance with Section 8.2 (Arbitration for Failure to Agree).

Time is Money Join Law Insider Premium to draft better contracts faster.